TRACON Pharmaceuticals Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $14.88 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
TRACON Pharmaceuticals Inc had its IPO on 2015-01-30 under the ticker symbol TCON.
The company operates in the Healthcare sector and Biotechnology industry. TRACON Pharmaceuticals Inc has a staff strength of 18 employees.
Shares of TRACON Pharmaceuticals Inc opened at $0.57 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $0.57 - $0.62, and closed at $0.62.
This is a +7.93% increase from the previous day's closing price.
A total volume of 97,252 shares were traded at the close of the day’s session.
In the last one week, shares of TRACON Pharmaceuticals Inc have increased by 0%.
TRACON Pharmaceuticals Inc's Key Ratios
TRACON Pharmaceuticals Inc has a market cap of $14.88 million, indicating a price to book ratio of 11.8258 and a price to sales ratio of 109.3933.
In the last 12-months TRACON Pharmaceuticals Inc’s revenue was $0 with a gross profit of $-13888000 and an EBITDA of $-25746000. The EBITDA ratio measures TRACON Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, TRACON Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -118.44% with a return of equity of -1277.01%.
In Q1, TRACON Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
TRACON Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.26 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into TRACON Pharmaceuticals Inc’s profitability.
TRACON Pharmaceuticals Inc stock is trading at a EV to sales ratio of 77.0468 and a EV to EBITDA ratio of -0.6975. Its price to sales ratio in the trailing 12-months stood at 109.3933.
TRACON Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $8.32 million
- Total Liabilities
- $14.18 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
TRACON Pharmaceuticals Inc ended 2023 with $8.32 million in total assets and $0 in total liabilities. Its intangible assets were valued at $8.32 million while shareholder equity stood at $-11072000.00.
TRACON Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $14.18 million in other current liabilities, 24000.00 in common stock, $-245415000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $6.61 million and cash and short-term investments were $6.61 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
TRACON Pharmaceuticals Inc’s total current assets stands at $7.14 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $0 and inventory worth $0.
In 2023, TRACON Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, TRACON Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
TRACON Pharmaceuticals Inc stock is currently trading at $0.62 per share. It touched a 52-week high of $2.32 and a 52-week low of $2.32. Analysts tracking the stock have a 12-month average target price of $8.25.
Its 50-day moving average was $1.2 and 200-day moving average was $1.53 The short ratio stood at 0.42 indicating a short percent outstanding of 0%.
Around 928.8% of the company’s stock are held by insiders while 4179.6% are held by institutions.
Frequently Asked Questions About TRACON Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company’s clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.